BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol 2017; 23(18): 3367-3373 [PMID: 28566898 DOI: 10.3748/wjg.v23.i18.3367]
URL: https://www.wjgnet.com/1007-9327/full/v23/i18/3367.htm
Number Citing Articles
1
Hiroki Tanabe, Keiichi Yoshino, Katsuyoshi Ando, Yoshiki Nomura, Katsuhisa Ohta, Kiichi Satoh, Eiichiro Ichiishi, Akiei Ishizuka, Takaaki Otake, Yutaka Kohgo, Mikihiro Fujiya, Toshikatsu Okumura. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradicationAnnals of Clinical Microbiology and Antimicrobials 2018; 17(1) doi: 10.1186/s12941-018-0281-x
2
Neil R. O'Morain, Maria P. Dore, Anthony J. P. O'Connor, Javier P. Gisbert, Colm A. O'Morain. Treatment of Helicobacter pylori infection in 2018Helicobacter 2018; 23(S1) doi: 10.1111/hel.12519
3
Antonio Moreno-Flores, Carmen Potel-Alvarellos, Maximiliano Álvarez-Fernández. Helicobacter pylori, antimicrobial resistance evolution 2012–2020 in Vigo sanitary area, Pontevedra, SpainEnfermedades infecciosas y microbiologia clinica (English ed.) 2021; 39(10): 523 doi: 10.1016/j.eimce.2021.09.004
4
Olga P. Nyssen, Marta Espada, Javier P. Gisbert. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-AnalysisFrontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.913436
5
Takuji Gotoda, Chika Kusano, Sho Suzuki, Toshiki Horii, Ryoji Ichijima, Hisatomo Ikehara. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in JapanJournal of Gastroenterology 2020; 55(10): 969 doi: 10.1007/s00535-020-01709-4
6
Luis Bujanda, Olga P. Nyssen, Dino Vaira, Ilaria M. Saracino, Giulia Fiorini, Frode Lerang, Sotirios Georgopoulos, Bojan Tepes, Frederic Heluwaert, Antonio Gasbarrini, Theodore Rokkas, Dmitry Bordin, Sinead Smith, Vincent Lamy, María Caldas, Elena Resina, Raquel Muñoz, Ángel Cosme, Ignasi Puig, Francis Megraud, Colm O’Morain, Javier P. Gisbert. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg)Antibiotics 2021; 10(9): 1058 doi: 10.3390/antibiotics10091058
7
Yu Huang, Jinnan Chen, Zhaohui Ding, Xiao Liang, Hong Lu. Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta‐analysisJournal of Gastroenterology and Hepatology 2022; 37(7): 1212 doi: 10.1111/jgh.15864
8
Zishao Zhong, Bingjie Zhan, Baohui Xu, Hengjun Gao. Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardizationHelicobacter 2022; 27(5) doi: 10.1111/hel.12916
9
Jaikirat Singh Gugnani, Fnu Abhishek, Yash Agarwal, Abhiram Rao Damera , Harkamalpreet Kaur, Bayan Taleb, Rohan Mane, Ujjwal Soni, Kapil D Nayar. Effectiveness of Rifabutin-Based Regimens in Treating Helicobacter pylori InfectionsCureus 2023;  doi: 10.7759/cureus.50541
10
Lyudmila Boyanova, Rumyana Markovska, Petyo Hadzhiyski, Nayden Kandilarov, Ivan Mitov. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent dataFuture Microbiology 2020; 15(12): 1185 doi: 10.2217/fmb-2020-0084
11
Mashiko Setshedi, Stella I. Smith. Helicobacter pylori Infection: Antibiotic Resistance and Solutions for Effective Management in AfricaAntibiotics 2023; 12(6): 969 doi: 10.3390/antibiotics12060969
12
Su Young Kim, Jun-Won Chung. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic ResistanceAntibiotics 2020; 9(8): 436 doi: 10.3390/antibiotics9080436
13
Tian Geng, Zhong-Su Yu, Xi-Xi Zhou, Bo Liu, Hui-Hua Zhang, Zhong-Yue Li. Antibiotic resistance of Helicobacter pylori isolated from children in Chongqing, ChinaEuropean Journal of Pediatrics 2022; 181(7): 2715 doi: 10.1007/s00431-022-04456-1
14
Shuai Zhou, Zhengqing Yang, Siqi Zhang, Yuanyuan Gao, Zhenping Tang, Yi Duan, Yalei Zhang, Yayi Wang. Metagenomic insights into the distribution, mobility, and hosts of extracellular antibiotic resistance genes in activated sludge under starvation stressWater Research 2023; 236: 119953 doi: 10.1016/j.watres.2023.119953
15
Elias Xirouchakis, Sotirios D. Georgopoulos. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic reviewExpert Opinion on Pharmacotherapy 2022; 23(2): 201 doi: 10.1080/14656566.2021.1982894
16
Meng-Shu Hsieh, Fu-Chen Kuo, Meng-Chieh Wu, Jiunn-Wei Wang, Chung-Jung Liu, Neng-Sheng Chu, Pei-Yun Tsai, Ping-I Hsu, I-Chen Wu, Jeng-Yih Wu, Deng-Chyang Wu, Fang-Jung Yu, Chao-Hung Kuo. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trialJournal of the Formosan Medical Association 2022; 121(8): 1450 doi: 10.1016/j.jfma.2021.10.011
17
Davide Ribaldone, Sharmila Fagoonee, Marco Astegiano, Marilena Durazzo, Anna Morgando, Tatiana Sprujevnik, Chiara Giordanino, Monica Baronio, Claudio De Angelis, Giorgio Saracco, Rinaldo Pellicano. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat PatientsJournal of Clinical Medicine 2019; 8(2): 199 doi: 10.3390/jcm8020199
18
Angel Cosme, Silvia Torrente Iranzo, Milagrosa Montes Ros, María Fernández‐Reyes Silvestre, Horacio Alonso Galán, Jacobo Lizasoain, Luis Bujanda. Helicobacter pylori antimicrobial resistance during a 5‐year period (2013‐2017) in northern Spain and its relationship with the eradication therapiesHelicobacter 2019; 24(1) doi: 10.1111/hel.12557
19
Sinéad M. Smith, Colm O’Morain, Deirdre McNamara. Helicobacter pylori resistance to current therapiesCurrent Opinion in Gastroenterology 2019; 35(1): 6 doi: 10.1097/MOG.0000000000000497
20
Javier P. Gisbert. Rifabutin for the Treatment of Helicobacter pylori Infection: A ReviewPathogens 2020; 10(1): 15 doi: 10.3390/pathogens10010015
21
Sho Suzuki, Mitsuru Esaki, Chika Kusano, Hisatomo Ikehara, Takuji Gotoda. Development of <i>Helicobacter pylori</i> treatment: How do we manage antimicrobial resistance?World Journal of Gastroenterology 2019; 25(16): 1907-1912 doi: 10.3748/wjg.v25.i16.1907
22
Antonio Moreno-Flores, Carmen Potel-Alvarellos, Maximiliano Álvarez-Fernández. Helicobacter pylori, evolución de la resistencia a antimicrobianos 2012-2020 en el área sanitaria de Vigo, Pontevedra, EspañaEnfermedades Infecciosas y Microbiología Clínica 2021; 39(10): 523 doi: 10.1016/j.eimc.2020.10.021
23
Cristina Paucar-Carrión, Marcela Espinoza-Monje, Cristian Gutiérrez-Zamorano, Kimberly Sánchez-Alonzo, Romina I. Carvajal, Cristian Rogel-Castillo, Katia Sáez-Carrillo, Apolinaria García-Cancino. Incorporation of Limosilactobacillus fermentum UCO-979C with Anti-Helicobacter pylori and Immunomodulatory Activities in Various Ice Cream BasesFoods 2022; 11(3): 333 doi: 10.3390/foods11030333